转移性结直肠癌维持治疗研究进展

结直肠癌是最常见的恶性肿瘤之一。近年来，奥沙利铂、5-FU类制剂、伊立替康、VEGF抗体、EGFR抑制剂等药物的使用延长了晚期结直肠癌患者的5年生存率，显著改善患者的生活质量。维持治疗是指对一线治疗后获益的患者，停用某些毒副反应较大的药物，保留低毒性药物继续治疗的一种治疗模式。因此，一些临床研究评估了上述药物在转移性结直肠癌患者一线治疗获益后的维持治疗的疗效及安全性。本文就转移性结直肠癌维持治疗方案的临床研究作一综述，全面地了解转移性结直肠癌维持治疗的相关进展。

Advances in research on maintenance therapy of metastatic colorectal cancer

Colorectal cancer (CRC) remains one of the most common common malignancy in the world.The introduction of the therapeutic agents such as oxaliplatin,5-fluoropyrimidines (5-FU),irinotecan,and vascular endothelial growth factor antibody and epidermal growth factor receptor (EGFR) inhibitors have significantly improved survival of patients with metastatic colorectal cancer (mCRC) in recent years.Maintenance therapy strategy is the strategy aimed to improve quality of life and survival with low toxicity drugs maintained after induction treatment.Therefore,some clinical studies have evaluated the efficacy and safety of the above-mentioned drugs after the first-line treatment benefit of patients with metastatic colorectal cancer.This article will review the clinical studies of mCRC maintenance treatment regimens so that we can get a more comprehensive view of the advances in the maintenance therapy of mCRC.